PE20030043A1 - Derivados acidos de azol sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo - Google Patents
Derivados acidos de azol sustituidos utiles como agentes antidiabeticos y antiobesidad y metodoInfo
- Publication number
- PE20030043A1 PE20030043A1 PE2002000455A PE2002000455A PE20030043A1 PE 20030043 A1 PE20030043 A1 PE 20030043A1 PE 2002000455 A PE2002000455 A PE 2002000455A PE 2002000455 A PE2002000455 A PE 2002000455A PE 20030043 A1 PE20030043 A1 PE 20030043A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- activator
- peroxisome
- proliferator
- azol
- Prior art date
Links
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title abstract 2
- 229940125708 antidiabetic agent Drugs 0.000 title abstract 2
- 239000003472 antidiabetic agent Substances 0.000 title abstract 2
- 230000003178 anti-diabetic effect Effects 0.000 title 1
- 239000000883 anti-obesity agent Substances 0.000 title 1
- 229940125710 antiobesity agent Drugs 0.000 title 1
- -1 AMINO Chemical class 0.000 abstract 3
- 239000012190 activator Substances 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 210000002824 peroxisome Anatomy 0.000 abstract 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 abstract 1
- 101710088194 Dehydrogenase Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 101100395338 Mus musculus Hmga2 gene Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960001761 chlorpropamide Drugs 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 229960004580 glibenclamide Drugs 0.000 abstract 1
- 229960000346 gliclazide Drugs 0.000 abstract 1
- 229960004346 glimepiride Drugs 0.000 abstract 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 abstract 1
- 229960001381 glipizide Drugs 0.000 abstract 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 206010024627 liposarcoma Diseases 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000003614 peroxisome proliferator Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29438001P | 2001-05-30 | 2001-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030043A1 true PE20030043A1 (es) | 2003-02-05 |
Family
ID=23133159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000455A PE20030043A1 (es) | 2001-05-30 | 2002-05-30 | Derivados acidos de azol sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20030092736A1 (enExample) |
| EP (1) | EP1390363A4 (enExample) |
| JP (1) | JP2004536070A (enExample) |
| AU (1) | AU2002259306B2 (enExample) |
| CA (1) | CA2449160A1 (enExample) |
| CZ (1) | CZ20033230A3 (enExample) |
| DE (1) | DE02729306T1 (enExample) |
| ES (1) | ES2214168T1 (enExample) |
| HU (1) | HUP0401504A3 (enExample) |
| MX (1) | MXPA03010997A (enExample) |
| NO (1) | NO327089B1 (enExample) |
| PE (1) | PE20030043A1 (enExample) |
| PL (1) | PL367066A1 (enExample) |
| TR (1) | TR200400650T3 (enExample) |
| TW (1) | TWI235061B (enExample) |
| UY (1) | UY27316A1 (enExample) |
| WO (1) | WO2002096358A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2495799A1 (en) * | 2002-08-21 | 2004-03-04 | Merck & Co., Inc. | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist |
| EP1424070A1 (en) * | 2002-11-28 | 2004-06-02 | Fournier Laboratories Ireland Limited | Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides |
| SE0300988D0 (sv) * | 2003-04-03 | 2003-04-03 | Astrazeneca Ab | New use |
| WO2004108126A1 (en) * | 2003-06-06 | 2004-12-16 | Snowden Pharmaceuticals, Llc | Fibric acid derivatives for the treatment of irritable bowel syndrome |
| MXPA06000118A (es) | 2003-07-08 | 2006-04-27 | Novartis Ag | Compuestos de bencensulfonamino y composiciones farmaceuticas que contienen estos compuestos. |
| RU2349587C2 (ru) * | 2003-09-22 | 2009-03-20 | Оно Фармасьютикал Ко., Лтд. | Производное фенилуксусной кислоты и его применение |
| US20070098778A1 (en) * | 2004-03-02 | 2007-05-03 | Abeille Pharmaceuticals, Inc. | Co-formulations or kits of bioactive agents |
| ATE493973T1 (de) | 2004-06-04 | 2011-01-15 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
| CN1304393C (zh) * | 2004-07-01 | 2007-03-14 | 中国药科大学 | 取代的吡唑啉酮衍生物及其制备方法与药用组合物 |
| KR100706600B1 (ko) * | 2004-11-25 | 2007-04-12 | 주식회사 엘지생명과학 | ＰＰＡＲ ｇａｍｍａ와 ＰＰＡＲ ａｌｐｈａ의 활성을항진시키는 신규 화합물, 그것의 제조방법, 및 그것을함유한 약제 조성물 |
| KR20060058632A (ko) * | 2004-11-25 | 2006-05-30 | 주식회사 엘지생명과학 | ＰＰＡＲ ｇａｍｍａ와 ＰＰＡＲ ａｌｐｈａ의 활성을항진시키는 신규 화합물, 그것의 제조방법, 및 그것을함유한 약제 조성물 |
| WO2007058504A1 (en) * | 2005-11-21 | 2007-05-24 | Lg Life Sciences, Ltd. | Novel compounds as agonist for ppar gamma and ppar alpha, method for preparation of the same, and pharmaceutical composition containing the same |
| US20090048199A1 (en) * | 2007-03-09 | 2009-02-19 | Hiberna Corporation | Hibernation-Related Genes and Proteins, Activators and Inhibitors Thereof and Methods of Use |
| BRPI0822349A2 (pt) * | 2007-11-29 | 2019-09-24 | Neuraltus Pharmaceuticals Inc | composições e métodos para tratar doenças lisossômicas |
| KR20110099687A (ko) * | 2008-10-29 | 2011-09-08 | 데시페라 파마슈티칼스, 엘엘씨. | 항-암과 항-증식성 활성을 나타내는 시클로프로판 아미드와 유사체 |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN109498622A (zh) * | 2018-12-28 | 2019-03-22 | 成都恒瑞制药有限公司 | 一种氯沙坦钾与罗格列酮组合物及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1003445B (zh) * | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物，其制备方法和用途 |
| US5591862A (en) * | 1993-06-11 | 1997-01-07 | Takeda Chemical Industries, Ltd. | Tetrazole derivatives, their production and use |
| AU782404B2 (en) * | 1999-04-28 | 2005-07-28 | Sanofi-Aventis Deutschland Gmbh | Tri-aryl acid derivatives as PPAR receptor ligands |
| AU7115300A (en) * | 1999-09-08 | 2001-04-10 | Glaxo Group Limited | Oxazole ppar antagonists |
| PL356487A1 (en) * | 1999-11-10 | 2004-06-28 | Takeda Chemical Industries, Ltd. | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| WO2002076959A1 (en) * | 2001-03-23 | 2002-10-03 | Takeda Chemical Industries, Ltd. | Five-membered heterocyclic alkanoic acid derivative |
-
2002
- 2002-05-22 US US10/153,454 patent/US20030092736A1/en not_active Abandoned
- 2002-05-23 MX MXPA03010997A patent/MXPA03010997A/es active IP Right Grant
- 2002-05-23 DE DE0001390363T patent/DE02729306T1/de active Pending
- 2002-05-23 WO PCT/US2002/016633 patent/WO2002096358A2/en not_active Ceased
- 2002-05-23 HU HU0401504A patent/HUP0401504A3/hu unknown
- 2002-05-23 CA CA002449160A patent/CA2449160A1/en not_active Abandoned
- 2002-05-23 PL PL02367066A patent/PL367066A1/xx not_active Application Discontinuation
- 2002-05-23 TR TR2004/00650T patent/TR200400650T3/xx unknown
- 2002-05-23 ES ES02729306T patent/ES2214168T1/es active Pending
- 2002-05-23 CZ CZ20033230A patent/CZ20033230A3/cs unknown
- 2002-05-23 AU AU2002259306A patent/AU2002259306B2/en not_active Ceased
- 2002-05-23 JP JP2002592871A patent/JP2004536070A/ja active Pending
- 2002-05-23 EP EP02729306A patent/EP1390363A4/en not_active Withdrawn
- 2002-05-24 TW TW091111100A patent/TWI235061B/zh not_active IP Right Cessation
- 2002-05-30 PE PE2002000455A patent/PE20030043A1/es not_active Application Discontinuation
- 2002-05-30 UY UY27316A patent/UY27316A1/es not_active Application Discontinuation
-
2003
- 2003-11-28 NO NO20035312A patent/NO327089B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20035312D0 (no) | 2003-11-28 |
| CZ20033230A3 (cs) | 2004-02-18 |
| HUP0401504A2 (hu) | 2004-11-29 |
| AU2002259306B2 (en) | 2007-02-08 |
| HUP0401504A3 (en) | 2008-05-28 |
| US20030092736A1 (en) | 2003-05-15 |
| NO327089B1 (no) | 2009-04-20 |
| UY27316A1 (es) | 2002-12-31 |
| TWI235061B (en) | 2005-07-01 |
| EP1390363A4 (en) | 2011-01-05 |
| WO2002096358A3 (en) | 2003-03-27 |
| PL367066A1 (en) | 2005-02-21 |
| WO2002096358A2 (en) | 2002-12-05 |
| MXPA03010997A (es) | 2004-02-27 |
| DE02729306T1 (de) | 2004-08-26 |
| ES2214168T1 (es) | 2004-09-16 |
| JP2004536070A (ja) | 2004-12-02 |
| TR200400650T3 (tr) | 2004-06-21 |
| EP1390363A2 (en) | 2004-02-25 |
| CA2449160A1 (en) | 2002-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030043A1 (es) | Derivados acidos de azol sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo | |
| ES2526463T3 (es) | Exendina para el tratamiento de la diabetes y la reducción del peso corporal | |
| EA200500080A1 (ru) | Дозированная форма прамипексола, принимаемая один раз в день | |
| RU2009112207A (ru) | Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью | |
| ES2216513T3 (es) | Nuevos analogos heterociclicos de compuestos de difeniletileno. | |
| PE20011056A1 (es) | Acidos ariloxiaceticos para la diabetes y trastornos de los lipidos | |
| ECSP034848A (es) | Derivados oxazol acido carboxilico sustituidos para uso como activadores ppar-alpha y -gamma en el tratamiento de diabetes | |
| AR015358A1 (es) | Antagonistas de la endotelina: n-[[2'-[[(4,5-dimetil-3-isoxazolil)amino]sulfonil]-4-(2-oxazolil)[1,1'-bifenil]-2-il]metil]-n,3,3-trimetilbutanamida yn-(4,5-demitil-3-isoxazolil)-2'-[(3,3-dimetil-2-oxo-1-pirrolidinil)metil]-4'-(2-oxazolil)[1,1'-bifenil]-2-sulfonamida y sales de los mismos y las compo | |
| CO5650227A2 (es) | Derivados del acido propionico utiles en desordenes lipidicos | |
| WO2001012187A3 (en) | Benzoic acid derivatives and their use as ppar receptor agonists | |
| PE20040655A1 (es) | Nuevos derivados de glicosido de tiofeno, procedimientos para su preparacion y medicamentos que los contienen | |
| ES2092890T3 (es) | Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson. | |
| PE20081557A1 (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos | |
| PA8562801A1 (es) | Nuevos derivados de pirido (2,1-a) isoquinolina | |
| NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
| BR0302584A (pt) | Combinação de brimonidina e timolol para uso oftálmico tópico | |
| PE20030989A1 (es) | Derivados de tiazol y oxazol que modulan la actividad de ppar | |
| ES2137260T3 (es) | Composicion farmaceutica para uso en el tratamiento del glaucoma. | |
| MX9400037A (es) | Composicion oftalmica para el tratamiento de glaucoma e hipertension ocular. | |
| AR032138A1 (es) | Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma | |
| PE20010478A1 (es) | Usos y composiciones de inhibidores de fosfodiesterasa tipo 5 del 3`,5'-guanosinmonofosfato ciclico para el tratamiento de enfermedades y condiciones del ojo | |
| AR012997A1 (es) | Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene. | |
| PE20020173A1 (es) | Uso de uno o mas antagonistas de aldosterona para el tratamiento o profilaxis de enfermedades mediadas por aldosterona | |
| RU2007139928A (ru) | Производное бензимидазола и применение в качестве антагониста ангиотензина | |
| EA200500691A1 (ru) | ПРИМЕНЕНИЕ АГОНИСТА ПЕРОКСИСОМА ПРОЛИФЕРАТОР-АКТИВИРОВАННОГО РЕЦЕПТОРА АЛЬФА (PPARα) И МЕТФОРМИНА ДЛЯ СНИЖЕНИЯ УРОВНЯ ТРИГЛИЦЕРИДОВ В СЫВОРОТКЕ КРОВИ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |